Biostax

Biostax P/TBV

Price to Tangible Book Value (P/TBV) of Biostax (BTAX) as of Nov 1, 2026.

P/TBV

-0.00

YoY

-37.43%

Last updated:

Price to Tangible Book Value (P/TBV) of Biostax is 2023 -0.00 . Price to Tangible Book Value (P/TBV) of Biostax was 2022 -0.00 . It decreases by -37.43% higher compared to the previous year.

The Biostax P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2016
-0.00 USD
Jan 1, 2017
-0.00 USD
Jan 1, 2018
-0.00 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.00 USD
Jan 1, 2023
-0.00 USD
The Biostax P/TBV history
YEARP/TBVYoY
-0.00-37.43%
-0.00+142.62%
-0.00+46.79%
-0.00+17.33%
-0.00-17.81%
-0.00-42.27%
-0.00-20.95%
-0.00-24.86%
-0.00-145.26%
0.01—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostax Stock analysis

What does Biostax do? Immune Therapeutics, Inc. develops and markets pharmaceutical, biotechnology, and MedTech products through its subsidiary BiostaxRx, which focuses on treating inflammaging disease. The company's product portfolio includes Londonal, a once-a-day immune system regulator for HIV/AIDS management, and JKB-122, a therapy targeting Autoimmune Hepatitis, NAFLD, and NASH with anti-fibrotic and anti-inflammatory properties. Biostax has partnerships in autoimmunity and immune restoration fields to deliver solutions for patients with autoimmunity, chronic inflammation, infection, and cancer. BiostaxRx specifically addresses inflammaging disease within its treatment focus. Biostax Corp's revenue streams come from the sale of Londonal and JKB-122 to healthcare providers and patients seeking treatments for immune-related conditions. The company markets its products to medical professionals and institutions specializing in autoimmune disorders, chronic inflammation, and oncology. Its focus on specific therapeutic areas allows it to target healthcare segments requiring immune modulation and anti-inflammatory solutions. The company's partnerships support its delivery of specialized treatments for chronic conditions such as HIV/AIDS, liver diseases, and cancer-related inflammation. The company's product lines are designed for specific patient segments including those with HIV/AIDS, Autoimmune Hepatitis, NAFLD, NASH, and inflammaging. Londonal is positioned for HIV/AIDS management while JKB-122 targets liver conditions and inflammation. BiostaxRx's focus on inflammaging disease aligns with the growing market for age-related immune health solutions. The company's marketing strategy emphasizes specialized treatments for complex conditions where current therapies are limited or ineffective. Biostax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostax stock

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Biostax since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Biostax with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biostax

All Key Metrics — Biostax